<DOC>
	<DOCNO>NCT02453594</DOCNO>
	<brief_summary>This study pembrolizumab ( MK-3475 ) participant relapsed/refractory classical Hodgkin Lymphoma ( RRcHL ) : 1 ) fail achieve response progress autologous stem cell transplant ( auto-SCT ) relapse treatment fail respond brentuximab vedotin ( BV ) post auto-SCT 2 ) unable achieve Complete Response ( CR ) Partial Response ( PR ) salvage chemotherapy receive auto-SCT , relapse treatment fail respond BV 3 ) fail achieve response progress auto-SCT received BV post auto-SCT . The primary study hypothesis treatment single agent pembrolizumab result clinically meaningful overall response rate .</brief_summary>
	<brief_title>Study Pembrolizumab ( MK-3475 ) Participants With Relapsed Refractory Classical Hodgkin Lymphoma ( MK-3475-087/KEYNOTE-087 )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Inclusion criterion : Relapsed refractory de novo classical Hodgkin lymphoma Participant may fail achieve response , progress , ineligible autologous stem cell transplant ( autoSCT ) Participant may fail achieve response progress treatment brentuximab vedotin may brentuximab vedotin na√Øve Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Measurable disease Adequate organ function Exclusion criterion : Diagnosis immunosuppression receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose study medication Prior monoclonal antibody within 4 week prior study Day 1 chemotherapy , target small molecular therapy , radiation therapy within 2 week prior study Day 1 Prior allogeneic hematopoietic stem cell transplantation Known clinically active central nervous system involvement Known additional malignancy progress require active treatment Has know history Human Immunodeficiency Virus ( HIV ) Has know active Hepatitis B ( HBV ) Hepatitis C ( HCV ) Active autoimmune disease require systemic treatment past 2 year Has history ( noninfectious ) pneumonitis require steroid , current pneumonitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PD1</keyword>
	<keyword>PD-1</keyword>
	<keyword>PDL1</keyword>
	<keyword>PD-L1</keyword>
</DOC>